KRAS and cancer: Previous studies found that the TP53 gene was a suppressor gene, its mutation had a significant impact on cancer risk, while KRAS mutation correlated with a low response rate to gefitinib in LUAD (Greathouse, et al., 2018; Reck, et al., 2021).